Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cheap clot drug save lives in blood cancer patients?

NCT ID NCT03136445

Disease control Sponsor: NHS Blood and Transplant Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether tranexamic acid, a drug that helps blood clot, can lower the risk of serious bleeding or death in people with blood cancers who have dangerously low platelet counts. Over 600 adults receiving chemotherapy or a stem cell transplant were randomly given either the drug or a placebo. The goal was to see if the drug could reduce the need for platelet transfusions and improve outcomes during the first 30 days of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

616 people

The number who actually took part.

Started

Jun 2015

Finished

Jun 2022

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients are eligible for this trial if: 1. Aged ≥18 years of age 2. Confirmed diagnosis of a haematological malignancy 3. Undergoing chemotherapy, or chemotherapy is planned, or haematopoietic stem cell transplantation 4. Anticipated to have a hypoproliferative thrombocytopenia resulting in a platelet count of ≤10x10⁹/L for ≥ 5 days 5. Able to comply with treatment and monitoring Exclusion Criteria: A patient will not be eligible for this trial if he/she fulfils one or more of the following criteria: 1. Patients with a past history or current diagnosis of arterial or venous thromboembolic disease including myocardial infarction, peripheral vascular disease and retinal arterial or venous thrombosis. 2. Diagnosis of acute promyelocytic leukaemia (APML) and undergoing induction chemotherapy 3. Patients with a diagnosis/previous history of veno-occlusive disease (also called sinusoidal obstruction syndrome) 4. Patients with known inherited or acquired prothrombotic disorders e.g. 1. Lupus anticoagulant 2. Positive antiphospholipids 5. Patients receiving any pro-coagulant agents (e.g. DDAVP, recombinant Factor VIIa or Prothrombin Complex Concentrates (PCC) within 48 hours of enrolment, or with known hypercoagulable state 6. Patients receiving L-asparaginase as part of their current cycle of treatment 7. History of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS) 8. Patients with overt disseminated intravascular coagulation (DIC) (See Appendix 3 in the protocol for definition) 9. Patients requiring a platelet transfusion threshold \>10x10/⁹L at time of randomisation. (This refers to patients who require their platelet count to be maintained at a certain specified level on an ongoing basis, and excludes a transient rise in the threshold due to sepsis.) 10. Patients with a known inherited or acquired bleeding disorder e.g. 1. Acquired storage pool deficiency 2. Paraproteinaemia with platelet inhibition 11. Patients receiving anticoagulant therapy or anti-platelet therapy 12. Patients with visible haematuria at time of randomisation 13. Patients with anuria (defined as urine output \< 10 mls/hr over 24 hours). 14. Patients with severe renal impairment (eGFR ≤30 ml/min/1.73m²) 15. Patients with a previous history of epilepsy, convulsions, fits or seizures 16. Patients who are pregnant or breast-feeding 17. Allergic to tranexamic acid. 18. Patients enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents. 19. Patients previously randomised into this trial at any stage of their treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic neoplasms Hematopoietic stem cell transplantation Hemorrhage

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Australia

  • Andrew Love Cancer Centre

    Geelong, Australia

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Belfast City Hospital

    Belfast, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom

  • Canberra Hospital

    Canberra, Australia

  • Churchill Hospital

    Oxford, United Kingdom

  • Derriford Hospital

    Plymouth, United Kingdom

  • Freeman Hospital

    Newcastle, United Kingdom

  • Heartlands Hospital

    Birmingham, United Kingdom

  • King's College Hospital

    London, United Kingdom

  • Lincoln County Hospital

    Lincoln, United Kingdom

  • Monash Health

    Melbourne, Australia

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Brisbane

    Brisbane, Australia

  • Royal Devon and Exeter Hospital

    Exeter, United Kingdom

  • Royal North Shore Hospital

    St Leonards, Australia

  • Royal United Hospital

    Bath, United Kingdom

  • Salisbury District Hospital

    Salisbury, United Kingdom

  • St James's Hospital

    Leeds, United Kingdom

  • St Vincent's Hospital

    Melbourne, Australia

  • St Vincent's Hospital

    Sydney, Australia

  • University College London Hospitals

    London, United Kingdom

  • University Hospital Coventry

    Coventry, United Kingdom

  • Victorian Comprehensive Cancer Centre

    Melbourne, Australia

  • Westmead Hospital

    Westmead, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.